Ask AI
Back Back
New Treatment Paradigm for cUTI
On the Horizon: A New Treatment Paradigm for cUTI

Released: July 02, 2026

Richard Colgan
Richard Colgan, MD
Activity Information

Activity

Key Takeaways
  • The 2025 Infectious Diseases Society of America guidelines for cUTI management provide HCPs with a structured framework for antibiotic selection and duration of antimicrobial therapy.
  • The oral carbapenem tebipenem pivoxil hydrobromide is now approved for cUTI and may reduce dependence on inpatient treatment by enabling effective oral step-down therapy or even complete outpatient management.
  • The combination of a fourth-generation cephalosporin and a novel β-lactam enhancer, cefepime-zidebactam, is a new IV option for severe infections caused by multidrug-resistant organisms, potentially preserving carbapenem use and expanding therapeutic choices.

The treatment landscape for complicated urinary tract infections (cUTI) has evolved significantly. In 2025, the Infectious Diseases Society of America (IDSA) released new guidance on cUTI management, which provides healthcare professionals (HCPs) with a structured framework for antibiotic selection and duration of therapy. The recommendations emphasize assessment of illness severity, evaluation of risk factors for resistant pathogens, consideration of patient-specific variables, and use of local antibiograms to guide empiric treatment.

These recommendations arrive at a critical time. Prevalence of multidrug-resistant Gram-negative organisms is rising in the United States and globally, along with associated morbidity and mortality. Fortunately, the therapeutic armamentarium has expanded with the recent approval of 2 new antibiotic agents: cefepime-zidebactam and tebipenem pivoxil hydrobromide.

Emerging Antimicrobial Agents
Cefepime-zidebactam, approved in May 2026, is a combination of a fourth-generation cephalosporin and a novel β-lactam enhancer. Zidebactam restores activity against organisms resistant to traditional β-lactam agents.

In the phase III ENHANCE-1 trial, cefepime-zidebactam achieved a composite clinical cure and microbiologic response rate of 89.0%, compared to 68.4% for meropenem. The safety profile was generally favorable and comparable to established IV β-lactam antibiotics. These results position cefepime-zidebactam as a valuable option for patients with drug-resistant Enterobacterales and other difficult-to-treat Gram-negative infections.

Tebipenem, approved in June 2026, represents a significant milestone in antibiotic development, as it is the first oral carbapenem approved for cUTI.

In clinical trials, tebipenem demonstrated comparable efficacy to intravenous carbapenems in patients with cUTI and acute pyelonephritis caused by susceptible organisms. The availability of an oral carbapenem enables outpatient management and creates opportunities for earlier hospital discharge. Adverse events were generally mild and consistent with other β-lactam antibiotics, with gastrointestinal effects among the most commonly reported.

A New Treatment Paradigm
The introduction of these agents has the potential to meaningfully alter treatment paradigms. Historically, patients with extended-spectrum β-lactamase–producing organisms or other resistant pathogens often required prolonged hospitalization for IV carbapenem therapy.

Tebipenem may reduce dependence on inpatient treatment by enabling effective oral step-down therapy or, in select patients, complete outpatient management.

Meanwhile, cefepime-zidebactam provides a potent new IV option for severe infections caused by multidrug-resistant organisms, potentially preserving carbapenem use and expanding therapeutic choices. 

Beyond their immediate clinical utility, these agents may have a significant impact on how we approach antimicrobial resistance. The availability of a reliable oral carbapenem challenges long-standing assumptions that highly resistant infections must be managed exclusively with inpatient IV therapy. In addition to potentially increasing convenience for patients, this shift has implications for healthcare resource utilization and antimicrobial stewardship. By facilitating earlier de-escalation from broad-spectrum IV agents and enabling targeted oral therapy, tebipenem may help reduce unnecessary exposure to hospital-based antimicrobials and decrease selective pressure within inpatient settings.

Similarly, cefepime-zidebactam introduces a novel antimicrobial mechanism that expands activity against resistant Gram-negative organisms, offering an alternative to traditional carbapenems in certain high-risk scenarios. This diversification of treatment options is critical in preserving the effectiveness of existing drug classes. We will be better equipped to tailor therapy based on resistance mechanisms rather than relying on a limited group of last-line agents.

However, the success of these advances will depend on thoughtful integration into clinical practice. Adherence to antibiotic stewardship principles such as appropriate patient selection and ongoing surveillance for emerging resistance will be essential to ensure that these new therapies remain effective for a long time. Operationalization of antimicrobial stewardship through pharmacy review and infectious disease consultation will be essential in determining the appropriateness of therapy. Thoughtful prescribing remains critical not only for individual patient outcomes, but also for the health of our communities. 

Taken together, the new IDSA cUTI guidance and the emergence of tebipenem and cefepime-zidebactam represent important advancements in the management of cUTI. As resistance patterns continue to evolve, these therapies offer HCPs greater flexibility to individualize treatment while supporting antimicrobial stewardship goals. The key challenge moving forward will be determining which patients are most likely to benefit from these novel agents while ensuring their responsible use to preserve effectiveness for years to come.

Your Thoughts
How are you planning to incorporate cefepime/zidebactam and tebipenem into your practice? What criteria do you think should be used to determine which patients are good candidates for these agents? Leave a comment to join the discussion!